NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Quarter Revenue Increased 17% to $137 Million FORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023. Highlights Consolidated revenue increased 17% to $137 million Clinical Services revenue increased 16% to $115 million Pharma Services revenue increased 22% to $22 million "Our business continued the momentum we saw in the fourth quarter of last year into the first quarter with accelerated double-digit revenue growth in both the Clinical and Pharma businesses," said Chris Smith, Chief Executive Officer of NeoGenomics.

NeoGenomics Reports First Quarter 2023 Results

FT. MYERS, FL / ACCESSWIRE / May 3, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada. NeoGenomics' management is scheduled to participate in a fireside chat on Wednesday, May 10th at 11:20 a.m.

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

Portillo's

Wingstop

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).

3 Top Stocks Likely to Exceed Estimates This Earnings Season

FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023. Along with the release, NeoGenomics will host a webcast and conference call that day at 4:30 p.m.

NeoGenomics to Announce First Quarter 2023 Financial Results

KE Holdings

Lamb Weston Hlds

Insperity

Surrozen

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

5 Top Stocks Likely to Come Up With Earnings Beat

FT. MYERS, FL / ACCESSWIRE / April 11, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that members of its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:00am ET. A live audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company's website at https://ir.neogenomics.com/.

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida. NeoGenomics, alongside collaborators, will present new data demonstrating the broad portfolio of services and available validated assays focused on tumor biology, including the use of RaDaR®, a personalized, highly-sensitive liquid biopsy sequencing test for the detection of minimal residual disease (MRD) and recurrence.

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET. The event will feature a presentation by NeoGenomics' executive team members and conclude with a Q&A session.

NeoGenomics to Host Investor Day on April 4, 2023

FT. MYERS, Fla. & NEW YORK--(BUSINESS WIRE)-- #AI--Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc.

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Calliditas Therapeutics AB

Reata Pharmaceuticals

Reata Pharmaceuticals stock is soaring on the back of a recent FDA approval for a new rare disease drug. Calliditas Therapeutics stock recently jumped higher in response to positive trial results for its lead drug.

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing

FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR ® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). MRD is the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment.

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms. "We are committed to offering a broad spectrum of next-generation tests paired with unparalleled service to enhance patient care," said Chris Smith, CEO of NeoGenomics.

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

Hims & Hers Health

International Seaways

Intapp

Lumen Technologies

Lyft

Turing Holding Corp

Vicor

Wayfair

Mid-cap stocks offer a balance between stability and growth prospects. On the one hand, they offer better growth prospects than large-cap stocks, and on the other, they carry lower risk and more stability than small-cap companies.

5 Best and Worst Performing Mid-Cap Stocks in February 2023

Allegro MicroSystems

Align Technology

Duolingo

Inter Parfums

NVIDIA

OneSpan Inc

Procore Technologies

Redfin

Roku

Shutterstock

Investors are worried that S&P 500 stocks will let them down. So why not focus on the handful that are delivering perfection?

Investors Cash In On 12 'Triple Play' Stocks That Do No Wrong

FT. MYERS, FL / ACCESSWIRE / February 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chris Smith, chief executive officer of NeoGenomics, and Jeff Sherman, chief financial officer, will participate in a fireside chat at the 44th Annual Raymond James Institutional Investors Conference on Monday, March 6, 2023 at 7:30am ET. A live audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company's website at https://ir.neogenomics.com/.

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

NeoGenomics, Inc. (NASDAQ:NEO ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Alex Nowak - Craig-Hallum Mark Massaro - BTIG Andrew Brackmann - William Blair Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Tom Stevens - Cowen Mason Carrico - Stephens Mike Matson - Needham & Company Andrew Cooper - Raymond James Operator Good morning. Welcome to the NeoGenomics Fourth Quarter and Full Year 2020 Earnings Conference Call.

NeoGenomics, Inc. (NEO) Q4 2022 Earnings Call Transcript

The company released promising earnings results.

Why Shares of NeoGenomics Jumped Today

NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million FORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2022 results for the period ended December 31, 2022. Highlights Fourth quarter consolidated revenue increased 10% to $139 million; Full year consolidated revenue increased 5% to $510 million Fourth quarter Clinical Services revenue increased 4% to $108 million; Full year Clinical Services revenue increased 4% to $419 million Fourth quarter Pharma Services revenue increased 41% to $31 million; Full year Pharma Services revenue increased 14% to $91 million "I am proud of the team's dedication to providing transformative cancer care for patients and providers and of the progress made in the fourth quarter as our organizational changes began to show results and we capped the year off with another sequential quarter of revenue, gross margin and adjusted EBITDA improvement.

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeoGenomics Laboratories, Inc. ("NeoGenomics" or "the Company") (NASDAQ: NEO). Investors who purchased NeoGenomics securities prior to November 9, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/neo.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NeoGenomics Laboratories, Inc. (NEO) Investigation

NEW YORK , Feb. 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, both dates inclusive (the "Class Period"), of the important February 6, 2023 lead plaintiff deadline. SO WHAT: If you purchased NeoGenomics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEO IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - NEO

New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities lawsuit.The lawsuit on behalf of NeoGenomics investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain NeoGenomics, Inc. securities between February 27, 2020 and April 26, 2022.

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO

Newly-published data shows a strong link between tumor DNA circulating in blood and patient responses to investigational neoadjuvant treatment with immune therapies FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced results of a new study of the RaDaR® assay in patients with muscle-invasive bladder cancer immediately following treatment with a combination of the immune checkpoint inhibitors in the neoadjuvant setting.

RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2022, financial results on Thursday, February 23, 2023. The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2022 results on Thursday, February 23, 2023 at 8:30 AM EDT.

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

NEW YORK , Feb. 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) and reminds investors of the February 6, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in NeoGenomics stock or options between February 27, 2020 and April 26, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

NEOGENOMICS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NeoGenomics To Contact Him Directly To Discuss Their Options

News for NeoGenomics Stock (NEO)